Invest on your own
Build your own portfolio, stock by stock.
We do it for you
Professionally managed portfolios, built and rebalanced for you.
NEW
How we screen every stock
Our halal screening & purification process in 3 minutes
Screeners
Your portfolio
Calculators
TOOL
Check any stock in seconds
Search 11,000+ tickers and see the halal verdict instantly.
Our certifications
Independent proof that every stock and portfolio meets halal standards.
METHODOLOGY
How we screen every stock
Our 5-step halal methodology, in 90 seconds.
Get help
NEW
Halal investing 101
A beginner-friendly intro to investing the halal way.
Plans by product
COMPARE
Find your plan
See every feature side-by-side and pick what fits.
Investors
INVESTORS
Invest in Musaffa
We're building the financial house for 1.9B Muslims. See the deck.
RGEN Shariah Compliance
Screening Methodology: AAOIFI
HALAL
Last Updated: May 11, 2026
Report Source: 2026 1st Quarter Report
Repligen Corp. Stock Analysis RGEN
United States Health Care Mid Cap Report: Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of manufacturing biological drugs. The company is headquartered in Waltham, Massachusetts and currently employs 2,000 full-time employees. Its franchises include filtration, chromatography, process analytics and proteins. Its filtration franchise includes product offering covering upstream and downstream technologies. Its filtration products include XCell Alternating Tangential Flow (ATF) Cell Retention Systems, Flat Sheet Cassettes, Hollow Fiber Consumables, Tangential Flow Filtration Systems and Fluid Management. Its chromatography franchise includes products used in downstream purification, development, manufacturing and quality control of biological drugs. Its chromatography franchise includes OPUS Pre-Packed Columns, KRM Chromatography Systems and other additional chromatography products. Its process analytics include Downstream process analytical technology (PAT) and Upstream PAT. Its Proteins include Protein A Affinity Ligands, AVIPure Resins for New Modalities and Growth Factors.
Read More Repligen Corp (RGEN) Chart
Key Statistics of Repligen Corp (RGEN)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$128.16Volume
856.50KP/E Ratio (TTM)
145.3752 Week Range
Market Cap
6.39BAvg. Volume
926.54KDividend Yield
-Financial Metrics & Statements of Repligen Corp (RGEN)
FAQ's for Repligen Corp (RGEN)
- According to Musaffa’s Shariah screening methodology, Repligen Corp (RGEN) is currently classified as HALAL as of May 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Repligen Corp using these criteria to determine its compliance status.
- Muslim investors may consider investing in Repligen Corp if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Repligen Corp by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Repligen Corp may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Repligen Corp on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.